Skip to main content

Advertisement

Table 1 Baseline characteristics for acute phase and maintenance phase samples

From: Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study

  Acute phase sample (n = 717) Maintenance phase sample (n = 459)
Gender, n (%)
 Female 308 (43.0) 200 (43.6)
 Male 409 (57.0) 259 (56.4)
Age, mean (SD) 42.9 (14.0) 42.7 (14.2)
BMI, mean (SD) 24.4 (4.9) 24.3 (4.8)
UC-DAI, mean (SD)
 Stool frequency (range: 0–3) 1.7 (0.8) 1.6 (0.8)
 Rectal bleeding severity (range: 0–3) 1.3 (0.7) 1.2 (0.7)
 Mucosal appearance (range: 0–3) 1.9 (0.5) 1.9 (0.5)
 Physician global assessment (range: 0–3) 1.6 (0.5) 1.6 (0.5)
 Total score (range: 0–12) 6.6 (1.6) 6.3 (1.5)
SF-12v2, mean (SD)
 Physical functioning 46.3 (9.1) 46.2 (9.1)
 Role physical 43.8 (7.9) 44.5 (7.5)
 Bodily pain 43.5 (9.1) 43.7 (8.7)
 General health 41.5 (10.1) 41.1 (9.8)
 Vitality 46.8 (9.5) 47.2 (8.9)
 Social functioning 42.4 (9.3) 43.1 (8.9)
 Role emotional 41.9 (9.6) 41.8 (9.4)
 Mental health 44.2 (9.4) 44.4 (9.0)
 PCS 44.9 (7.7) 45.0 (7.6)
 MCS 43.1 (9.2) 43.5 (8.9)
SIBDQ, mean (SD)
 Bowel symptoms (range: 3–21) 12.6 (3.1) 12.8 (3.1)
 Systemic symptoms (range: 2–14) 8.9 (2.6) 9.1 (2.5)
 Emotional function (range: 3–21) 12.8 (3.9) 13.1 (3.8)
 Social function (range: 2–14) 8.9 (3.0) 9.2 (2.9)
 Total score (range: 10–70) 43.2 (10.6) 44.1 (10.4)
WPAI:UC, mean (SD); range (0–100)
 Absenteeism 13.3 (24.0) 12.3 (22.2)
 Presenteeism 36.1 (24.5) 32.7 (22.8)
 Overall work impairment 42.2 (28.2) 39.1 (26.6)
 Activity impairment 41.5 (25.6) 38.9 (24.7)
  1. BMI body mass index, MCS mental component summary, PCS physical component summary, SD standard deviation, SF-12v2 SF-12v2 Health Survey, SIBDQ Short Inflammatory Bowel Disease Questionnaire, UC-DAI Ulcerative Colitis Disease Activity Index, WPAI:UC Work Productivity and Activity Impairment questionnaire for ulcerative colitis